A group of companies from Germany are scouting for partners in the domestic pharma industry for opportunities in areas of research and development, production and sales and distribution. The group includes Orgentis Chemicals Ltd, Organica Fine Chemicals, Synthon Chemicals and biotech company c-Lecta, which are in talks with some leading Indian pharma companies to forge R&D partnerships.
Harold Wolf, a representative of the five companies who was in India recently, told pharmquest.biz that talks on an investment in the area of fine chemicals are in advanced stages and an announcement is likely sometime next year.
He refused to divulge any further details.
"In the past decades, India has built an interesting branch structure with global leaders. India has the same spirit to create excellence in academia and research. For the companies in our cluster, India is a very interesting strategic partner and could generate further markets in Asia," added Wolf.
"These companies are targeting long-term engagement of developing products with Indian companies. However, conventionally speaking in the pharma landscape, before adopting such projects of large scale, the companies do take up small projects together," said Anandi Iyer, CEO, Investment Innovation and Research Alliance, the Bangalore-based organisation that is arranging for the talks between Indian and German players.
"India offers a new and promising market for our innovations and products. We want to strengthen existing contacts and continue to attract new Indian partners for cooperation in the field of innovative chemistry," said Hans-Matthias Vorbrodt, managing director of Orgentis Chemicals Ltd, manufacturer of specialty chemicals, which works in the insulin vertical among others.
"We are looking for new opportunities in India to offer our research, development and production services in the area of highly complex organic synthesis," said Bodo Schulze, chief executive officer of Organica Fine Chemicals GmbH, a company that offers custom manufacturing of advanced organic intermediates to major pharmaceutical and industrial companies around the world. Apart from talking to players in the pharmaceuticals and industrial biotech sectors, some of the German companies are also exploring opportunities in the textile and electronic industries.